Quote this publication Share Print

VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza

Opinions on drugs - Posted on Apr 12 2018

Reason for request


No clinical benefit demonstrated relative to trivalent inactivated vaccines


  • VAXIGRIPTETRA is an inactivated, split-virion, injectable vaccine with Marketing Authorisation in the active immunisation of adults and children aged 3 years and over for the prevention of influenza caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.
  • It differs from trivalent influenza vaccines by the addition of a second type B strain, but there is no evidence for its preference over inactivated trivalent vaccines.




Clinical Benefit



Clinical Added Value

no clinical added value


Contact Us

Évaluation des médicaments